Shares of Johnson & Johnson (JNJ) declined during Monday's trading session, underperforming the broader U.S. equity market as the healthcare sector faced notable pressure. The stock closed the day down approximately 1.1% at $237.45, retreating from an intraday peak of $240.74 and touching a low of $237.29. Trading volume was active, with roughly 3.2 million shares changing hands.
Healthcare Sector Underperforms
The weakness in JNJ was part of a broader sector-wide decline. The Health Care Select Sector SPDR Fund (XLV), a key ETF tracking major U.S. healthcare companies, fell nearly 1%. Peer pharmaceutical giants experienced steeper losses, with Merck & Co. (MRK) dropping 3.6% and Amgen (AMGN) shedding around 2.9%. This collective downturn stood in stark contrast to the resilience of the broader market, where the SPDR S&P 500 ETF (SPY) gained about 0.6% and the Invesco QQQ Trust (QQQ), which tracks the Nasdaq-100, advanced roughly 0.9%.
The divergence is particularly noteworthy given Johnson & Johnson's typical reputation as a stable, dividend-paying defensive stock. The sell-off appears to reflect a rotation away from defensive plays following a strong market surge late last week that propelled the Dow Jones Industrial Average above the 50,000 milestone for the first time. With a busy calendar of U.S. economic data and corporate earnings on the horizon, traders are quickly adjusting their positions.
Recent Performance and Forward Guidance
The retreat comes after a period of significant strength for JNJ shares. According to data from Simply Wall St, the stock had surged 17.42% over the preceding month, with its total return for the year reaching an impressive 61.53%. Such robust gains often lead investors to secure profits when sector momentum falters, contributing to the day's pullback.
In its latest quarterly report, Johnson & Johnson provided financial projections for the full year 2026. The company forecasts sales in a range of $99.5 billion to $100.5 billion. Adjusted earnings per share are expected to land between $11.43 and $11.63. CEO Joaquin Duato expressed confidence, stating the company anticipates faster growth in 2026 compared to 2025. However, CFO Joseph Wolk noted that a pending U.S. drug-pricing agreement could potentially cost the firm "hundreds of millions of dollars," introducing a note of caution to the outlook.
Dividend Details and Legal Overhang
Investors have a near-term positive catalyst with an upcoming dividend payment. The company's board authorized a first-quarter cash dividend of $1.30 per share, scheduled for payment on March 10. To be eligible, shareholders must be on record by February 24, which also serves as the ex-dividend date—the cutoff for purchasing shares and still qualifying for the payout.
Despite its fundamental operations, Johnson & Johnson continues to navigate significant legal challenges. The company is contending with more than 67,500 lawsuits alleging that its talc-based products caused cancer. In a recent development, a New Jersey appeals court barred a plaintiffs' law firm from participating in state-level cases due to an ethics violation. The firm has indicated it will appeal this decision, ensuring the legal saga remains a persistent overhang.
Macroeconomic Backdrop and Key Data Ahead
Broader economic concerns also influenced market sentiment. A survey released Monday by the Federal Reserve Bank of New York indicated that one-year inflation expectations softened in January, suggesting underlying shifts in the interest rate outlook even if equity markets have not fully reflected them.
Market participants are now keenly focused on two critical economic releases later this week. The U.S. Bureau of Labor Statistics will publish the January employment report on Wednesday, followed by the Consumer Price Index (CPI) data for January on Friday. Both reports are scheduled for 8:30 a.m. Eastern Time. This data will be crucial in shaping expectations for Federal Reserve policy and could significantly influence the trajectory of defensive and dividend-oriented stocks like JNJ in the coming days.
